Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) received a €17.10 ($18.39) price target from equities research analysts at JPMorgan Chase & Co. in a report released on Wednesday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price target would suggest a potential downside of 48.04% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the company. Morgan Stanley set a €34.00 ($36.56) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, October 18th. Berenberg Bank set a €49.05 ($52.74) price objective on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, November 29th. Credit Suisse Group set a €32.00 ($34.41) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, November 8th. UBS Group set a €30.00 ($32.26) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, December 6th. Finally, Jefferies Financial Group set a €22.00 ($23.66) target price on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday.
Fresenius Medical Care AG & Co. KGaA Trading Up 0.5 %
ETR FME opened at €32.91 ($35.39) on Wednesday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of €25.95 ($27.90) and a fifty-two week high of €63.60 ($68.39). The company has a debt-to-equity ratio of 82.37, a quick ratio of 0.80 and a current ratio of 1.34. The stock has a 50 day simple moving average of €30.03 and a two-hundred day simple moving average of €33.76. The stock has a market cap of $9.66 billion and a P/E ratio of 12.60.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy’s Stock Uptrend Set To Continue?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.